[{"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Global and Australian update", "description": "Omicron moves into a vacinate population", "link": "https://www.youtube.com/watch?v=Y7ToJMLkeDc", "date_published": "2022-03-16 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}, {"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Superior natural immunity", "description": "Scotland, mask mandates\n\nhttps://www.telegraph.co.uk/news/2022/03/15/scotland-keep-face-masks-another-two-weeks-due-spike-cases/?WT.mc_id=e_DM1551567&WT.tsrc=email&etype=Edi_GHS_New_Daily&utmsource=email&utm_medium=Edi_GHS_New_Daily20220315&utm_campaign=DM1551567\n\nNicola Sturgeon, \u201cprudent\u201d \n\nmandatory mask rules, until April 4 at the earliest.\n\nMask rules, case numbers well ahead of England\n\nhttps://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19/latestinsights\n\n2,073,900 people (1 in 25) in England\n\n97,900 people (1 in 30) in Wales\n\n143,800 people (1 in 13) in Northern Ireland\n\n299,900 people (1 in 18) in Scotland\n\nCOVID-19: Why Are We Ignoring Infection-Acquired Immunity?\n \nhttps://www.medscape.co.uk/viewarticle/covid-19-why-are-we-ignoring-infection-acquired-immunity-2022a1000ifd?uac=127834AR&faf=1&sso=true&impID=4086722&src=mkm_ret_220315_mscpmrk_perspectiveuk_int\n\nAntibodies from natural infection, more abundant, more potent, at least 10 times more potent, than immunity generated by vaccination alone \n\nHybrid immunity, induces a sort of 'super-immunity',\n\nirrespective of whether infection or vaccination comes first, \n\nthere is increasing evidence that immunity derived from natural infection with COVID-19 gives powerful protection on its own. \n\nNatural immunity has been shown to be both highly protective and long lasting, \n\nand to safeguard against both re-infection and severe disease.\n\nVaccination before or after SARS-CoV-2 infection leads to robust humoral response and antibodies that effectively neutralize variants\n\n(Oregon Health & Science University (OHSU) Portland, US\n\nhttps://www.science.org/doi/10.1126/sciimmunol.abn8014\n\nAntibody responses from the initial wave of vaccines in early 2021 have waned over 6 months,\n\ncontributing to an increase in breakthrough infections\n\nWe measure neutralizing antibody responses\n\nThose with breakthrough infections \n\nHybrid immunity\n\nNo infection history\n\nWe find that human immune sera \n\nAfter breakthrough infection and vaccination\n\nAfter natural infection\n\nbroadly neutralize variants to a similar degree\n\nAge \n\nNegatively correlates with antibody response after vaccination alone, \n\nno correlation with age was found in breakthrough or hybrid immune groups. \n\nTogether, our data suggest that the additional antigen exposure from natural infection substantially boosts the quantity, quality, and breadth of humoral immune response regardless of whether it occurs before or after vaccination\n\nCOVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis \u2014 California and New York, May\u2013November 2021\n\nhttps://www.cdc.gov/mmwr/volumes/71/wr/mm7104e1.htm\n\nBy early October, \n\npersons who survived a previous infection\n\nhad lower case rates than \n\npersons who were vaccinated alone.\n\nNatural immunity against COVID-19 significantly reduces the risk of reinfection: findings from a cohort of sero-survey participants (India)\n\nhttps://www.medrxiv.org/content/10.1101/2021.07.19.21260302v1.full.pdf\n\nstrong plausibility that development of antibody following natural infection not only protects against re-infection by the virus to a great extent,\n\nbut also safeguards against progression to severe COVID-19 disease\n\nEU drug regulator expresses doubt on need for fourth booster dose\n\nhttps://www.reuters.com/business/healthcare-pharmaceuticals/eu-drug-regulator-says-more-data-needed-impact-omicron-vaccines-2022-01-11/\n\nEuropean Medicines Agency, Head of Vaccines Strategy, Marco Cavaleri\n\nWhile use of additional boosters can be part of contingency plans, \n\nrepeated vaccinations within short intervals would not represent a sustainable long-term strategy\n\nBoosters every four months,\n\nposes the risk of overloading people's immune systems,\n\nand leading to fatigue in the population.\n\nThere is a need for an updated vaccine,\n\nany such change would need to be coordinated globally.", "link": "https://www.youtube.com/watch?v=kkjBi7dOTAg", "date_published": "2022-03-16 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}]